EFPIA - NEWSLETTER

EFPIA Newsletter 28 March 2024

News

28 March 2024 Guidance needed to ensure EU Joint Clinical Assessment improves patient access to innovative...

New study simulating proposed EU HTA methods for oncology medicines underlines need for guidance on Joint Clinical Assessment...

28 March 2024 NIRO: Navigating Innovation & Research Opportunities

NIRO helps you find available European and international funds for research & innovation.

Blogs

26 March 2024 Innovative Health Initiative: improving health, improving healthcare

From managing obesity to supporting healthier pregnancy, IHI is advancing people’s health and making health systems...

Events

04 APR 2024

Unlocking the Human Element: Integrating Patient Insights & Experiences into Precision... Virtual event

Organised by the Patient Engagement Open Forum (PEOF), in collaboration with EFPIA and EPF.

Learn more →

12 APR 2024

EU-X-CT Public Stakeholders' Forum Brussels and online

Making cross-border access to clinical trials a reality

Learn more →

What we are reading

A Compass for Collaboration: Navigating Stakeholders’ Roles in Transitioning To Value-Based... 26 March 2024 (European Alliance for Value in Health)

IMI-supported treatment against drug-resistant bacteria receives positive opinion from EMA 22 March 2024 (IHI)

Diagnostic research needs recommendations 18 December 2023 (Rare Disease Moonshot)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶